Bloodstream infections (BSIs) are severe systemic infections that occur when pathogenic microorganisms enter the circulatory system, triggering widespread inflammation and potentially leading to sepsis, septic shock, or multi-organ failure. According to the World Health Organization, sepsis remains a major global cause of morbidity and mortality, particularly in hospitalized and immunocompromised patients. Early diagnosis, blood culture testing, and prompt antimicrobial therapy are critical for survival. Broad-spectrum antibiotics such as ceftriaxone are frequently administered intravenously; therefore, selecting a reliable ceftriaxone injection supplier is essential to ensure drug quality, sterility, and consistent therapeutic efficacy in managing bloodstream infections.